Literature DB >> 12482029

Mutation of glutamic acid residue 1046 abolishes Jak2 tyrosine kinase activity.

Dannielle VonDerLinden1, Xianyue Ma, Eric M Sandberg, Kim Gernert, Kenneth E Bernstein, Peter P Sayeski.   

Abstract

Jak2 is a member of the Janus family of tyrosine kinases and is known to be activated by a wide variety of ligands. Here, we sought to identify amino acid residues within Jak2 that are essential for its activation. We provide evidence that glutamic acid 1046 (E1046) is one such residue. Using molecular modeling algorithms of the Jak2 kinase domain, we identified a putative molecular interaction between E1046 and tryptophan 1020 (W1020). Conversion of E1046 to either arginine (E 1046R), alanine (E1046A), aspartic acid (E1046D) or glutamine (E1046Q) abolished Jak2 kinase activity as measured by autophosphorylation assays. Conversion of W1020 to glycine (W1020G) similarly abolished Jak2 kinase activity. Finally, we tested the ability of the E1046R mutant to activate the Jak/STAT signaling pathway in a ligand-dependent signaling system. The ability of angiotensin II to activate the Jak/STAT signaling pathway in cells expressing the E1046R mutant was severely compromised as measured by reduced (1) Jak2 autophosphorylation (2) Jak2 kinase activity (3) AT1/Jak2 co-association (4) Stat1 tyrosine phosphorylation and (5) angiotensin Il-mediated gene transcription. Thus, these studies demonstrate for the first time, the critical role of E1046 in mediating Jak2 activation and its subsequent downstream signaling events.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12482029     DOI: 10.1023/a:1020829617779

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.842


  21 in total

1.  A catalytically active Jak2 is required for the angiotensin II-dependent activation of Fyn.

Authors:  P P Sayeski; M S Ali; A Safavi; M Lyles; S O Kim; S J Frank; K E Bernstein
Journal:  J Biol Chem       Date:  1999-11-12       Impact factor: 5.157

Review 2.  Structural and mechanistic aspects of Janus kinases: how the two-faced god wields a double-edged sword.

Authors:  R J Duhé; W L Farrar
Journal:  J Interferon Cytokine Res       Date:  1998-01       Impact factor: 2.607

3.  Jak2 acts as both a STAT1 kinase and as a molecular bridge linking STAT1 to the angiotensin II AT1 receptor.

Authors:  M S Ali; P P Sayeski; K E Bernstein
Journal:  J Biol Chem       Date:  2000-05-19       Impact factor: 5.157

4.  Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor.

Authors:  N Meydan; T Grunberger; H Dadi; M Shahar; E Arpaia; Z Lapidot; J S Leeder; M Freedman; A Cohen; A Gazit; A Levitzki; C M Roifman
Journal:  Nature       Date:  1996-02-15       Impact factor: 49.962

5.  The angiotensin II-dependent association of Jak2 and c-Src requires the N-terminus of Jak2 and the SH2 domain of c-Src.

Authors:  P P Sayeski; M S Ali; K Hawks; S J Frank; K E Bernstein
Journal:  Circ Res       Date:  1999-06-11       Impact factor: 17.367

6.  Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop.

Authors:  J Feng; B A Witthuhn; T Matsuda; F Kohlhuber; I M Kerr; J N Ihle
Journal:  Mol Cell Biol       Date:  1997-05       Impact factor: 4.272

7.  Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation.

Authors:  K Lindauer; T Loerting; K R Liedl; R T Kroemer
Journal:  Protein Eng       Date:  2001-01

8.  Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor.

Authors:  W S Chen; C S Lazar; M Poenie; R Y Tsien; G N Gill; M G Rosenfeld
Journal:  Nature       Date:  1987 Aug 27-Sep 2       Impact factor: 49.962

9.  Kinase-negative mutants of JAK1 can sustain interferon-gamma-inducible gene expression but not an antiviral state.

Authors:  J Briscoe; N C Rogers; B A Witthuhn; D Watling; A G Harpur; A F Wilks; G R Stark; J N Ihle; I M Kerr
Journal:  EMBO J       Date:  1996-02-15       Impact factor: 11.598

10.  Inhibition of erythropoietin-induced mitogenesis by a kinase-deficient form of Jak2.

Authors:  H Zhuang; S V Patel; T C He; S K Sonsteby; Z Niu; D M Wojchowski
Journal:  J Biol Chem       Date:  1994-08-26       Impact factor: 5.157

View more
  4 in total

1.  The mouse mutants recoil wobbler and nmf373 represent a series of Grm1 mutations.

Authors:  Andrew J Sachs; Jamie K Schwendinger; Andy W Yang; Neena B Haider; Arne M Nystuen
Journal:  Mamm Genome       Date:  2007-10-13       Impact factor: 2.957

2.  In vivo inactivation of MASTL kinase results in thrombocytopenia.

Authors:  H Jan Johnson; Manish J Gandhi; Ebrahim Shafizadeh; Nathaniel B Langer; Eric L Pierce; Barry H Paw; Diana M Gilligan; Jonathan G Drachman
Journal:  Exp Hematol       Date:  2009-05-19       Impact factor: 3.084

3.  Thrombocytopenia-associated mutations in Ser/Thr kinase MASTL deregulate actin cytoskeletal dynamics in platelets.

Authors:  Begoña Hurtado; Marianna Trakala; Pilar Ximénez-Embún; Aicha El Bakkali; David Partida; Belén Sanz-Castillo; Mónica Álvarez-Fernández; María Maroto; Ruth Sánchez-Martínez; Lola Martínez; Javier Muñoz; Pablo García de Frutos; Marcos Malumbres
Journal:  J Clin Invest       Date:  2018-10-29       Impact factor: 14.808

4.  Jak2 tyrosine kinase residues glutamic acid 1024 and arginine 1113 form a hydrogen bond interaction that is essential for Jak-STAT signal transduction.

Authors:  Eric M Sandberg; Dannielle VonDerLinden; David A Ostrov; Peter P Sayeski
Journal:  Mol Cell Biochem       Date:  2004-10       Impact factor: 3.842

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.